PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2020 Financial Results
May 04 2020 - 8:30AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company’s proprietary
Versamune® T-cell activating technology, today announced that the
Company will release financial results for the first quarter ended
March 31, 2020 on Wednesday, May 13, 2020, before the market opens.
Following the release, Dr. Frank Bedu-Addo, Chief Executive
Officer, will host a conference call to review the financial
results and provide a business update.
The conference call is scheduled to begin at
8:00 am ET on Wednesday, May 13, 2020. Participants should dial
877-407-3088 (United States) or 201-389-0927 (International) and
mention PDS Biotechnology. A live webcast of the conference call
will also be available on the investor relations page of the
Company's corporate website at www.pdsbiotech.com.
After the live webcast, the event will be
archived on PDS Biotech’s website for 6 months. In addition, a
telephonic replay of the call will be available for 6 months. The
replay can be accessed by dialing 877-660-6853 (United States) or
201-612-7415 (International) with confirmation code 13703263.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy
company with a growing pipeline of cancer immunotherapies and
infectious disease vaccines based on the Company’s proprietary
Versamune® T-cell activating technology platform. Versamune®
effectively delivers disease-specific antigens for in vivo uptake
and processing, while also activating the critical type 1
interferon immunological pathway, resulting in production of potent
disease-specific killer T-cells as well as neutralizing antibodies.
PDS Biotech has engineered multiple therapies, based on
combinations of Versamune® and disease-specific antigens, designed
to train the immune system to better recognize disease cells and
effectively attack and destroy them. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Media & Investor Relations
Contact:
Deanne RandolphPDS BiotechPhone: +1 (908)
517-3613Email: drandolph@pdsbiotech.com
Tram Bui / Alexander LoboThe Ruth GroupPhone: +1
(646) 536-7035 / +1 (646) 536-7037Email: tbui@theruthgroup.com /
alobo@theruthgroup.com
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Mar 2024 to Apr 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2023 to Apr 2024